Status:
COMPLETED
Trehalose Administration in Subjects With Spastic Paraplegia 11 (3AL-SPG11)
Lead Sponsor:
IRCCS Fondazione Stella Maris
Conditions:
Hereditary Spastic Paraplegia
Spastic Paraplegia Type 11
Eligibility:
All Genders
10+ years
Brief Summary
Hereditary spastic paraparesis type 11 (SPG11) is caused by mutations in the SPG11 gene that produces spatacsin, a protein involved in lysosomal function.
Detailed Description
Several experiments on subjects affected by neurodegenerative diseases with dysfunction of the autophagic-lysosomal system show that trehalose improves the pathological phenotype. This evidence indica...
Eligibility Criteria
Inclusion
- Confirmed diagnosis of SPG11
- Written signed informed consent
Exclusion
- Diagnosis of other concomitant neurodegenerative diseases
- taking other experimental drugs within 30 days of the first Study visit (T0) and during the study
- Refusal to sign informed consent
Key Trial Info
Start Date :
June 30 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 30 2022
Estimated Enrollment :
13 Patients enrolled
Trial Details
Trial ID
NCT04912609
Start Date
June 30 2021
End Date
July 30 2022
Last Update
August 3 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
IRCCS Fondazione Stella Maris
Pisa, PI, Italy, 56128